{
  "meta": {
    "timestamp": "2025-01-06T14:06:32.501638",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Kronos Bio Inc",
      "symbol": "KRON",
      "analysis": {
        "historical": {
          "risk_score": 85,
          "key_risks": [
            "Clinical trial failures and pipeline setbacks, including discontinuation of lead asset istisociclib due to safety concerns and poor efficacy of lanraplenib",
            "Severe financial strain with an 83% workforce reduction and exploration of strategic alternatives",
            "Regulatory hurdles and intense competitive landscape in oncology and precision medicine",
            "Leadership changes and strategic uncertainty"
          ],
          "controversies": [
            "Safety concerns in Phase I/II trial for istisociclib, with neurological adverse events reported in five out of seven patients",
            "Halted mid-stage trial for lanraplenib due to poor efficacy"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Significant workforce reduction impacting employees and company morale"
          ],
          "governance_issues": [
            "Leadership changes, including a CEO transition, amid restructuring efforts"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Kronos discontinues mid-stage AML trial after poor response",
              "snippet": "After a mid-stage flop, Kronos Bio is discontinuing a cancer trial for lanraplenib and seeking a partner to continue development of the SYK inhibitor\u2014the second acute myeloid leukemia (AML ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502512+00:00",
              "published_date": null,
              "source_hash": "1e069e2cfad9afc37ba8745f72b8587b"
            },
            {
              "url": "",
              "title": "Struggling Bay Area biotech firm Kronos, once worth $1B, lays off ...",
              "snippet": "Kronos Bio, a struggling Bay Area biotech firm once valued at over $1 billion, is laying off 83% of its staff after other cuts and a failed trial. ... Kronos discontinued a clinical trial for ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:05:59.769826+00:00",
              "published_date": null,
              "source_hash": "6b0e24b63a965cf56734eb87c43d6877"
            },
            {
              "url": "",
              "title": "Kronos mulls 'strategic alternatives' after axing cancer drug development",
              "snippet": "Kronos Bio has discontinued the development of its last remaining clinical asset, istisociclib (KB-0742), after a review of the safety data from a Phase I/II trial in patients with platinum-resistant high-grade serous ovarian cancer.. Out of the seven patients enrolled in the Phase I/II trial (NCT04718675) of the cyclin-dependent kinase 9 (CDK9) inhibitor, five reported neurological adverse ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502382+00:00",
              "published_date": null,
              "source_hash": "59b8d12d12d7cc9af9485b9bf2e34efe"
            },
            {
              "url": "",
              "title": "Kronos Bio explores significant cost cuts after pulling out of sole ...",
              "snippet": "Kronos Bio has already conducted two rounds of layoffs in the past 12 months, cutting 21% of its staff in March and 19% in November of last year.. While the company reported $124.9 million in cash ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:05:59.769853+00:00",
              "published_date": null,
              "source_hash": "58d4cef257bf73d61a3a2db94d698597"
            },
            {
              "url": "",
              "title": "Kronos Bio: Still Promising But Riskier Following ASCO Update",
              "snippet": "An update on the disappointing ph2 study of KB-0742, highlighting potential efficacy and safety concerns, as well as future catalysts for Kronos Bio. Learn more on KRON stock here.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502502+00:00",
              "published_date": null,
              "source_hash": "0a37ab88429cdaff4cdc01f04d071114"
            },
            {
              "url": "",
              "title": "Kronos cuts 19% of staff to make way for solid tumor drug - Fierce Biotech",
              "snippet": "Separately, Kronos announced the presentation of early data from a dose-escalation portion of a phase 1/2 trial for KB-0742 showing anti-tumor activity. Kronos said the data confirmed earlier ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691573+00:00",
              "published_date": null,
              "source_hash": "bb140b52a6cdbc61a3fb500f765e2cce"
            },
            {
              "url": "",
              "title": "Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure ...",
              "snippet": "About Kronos Bio, Inc. Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor KB-0742 as a treatment for MYC-dependent solid tumors and other transcriptionally addicted solid tumors and lanraplenib, a next-generation SYK ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:05:59.769882+00:00",
              "published_date": null,
              "source_hash": "879304314c7807832666845ddf57fcf8"
            },
            {
              "url": "",
              "title": "Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on ...",
              "snippet": "Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4. With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 ... Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:05:59.769894+00:00",
              "published_date": null,
              "source_hash": "842995ad93b66fe0cf7c597acc0697d2"
            },
            {
              "url": "",
              "title": "Clinical Trials - Kronos Bio",
              "snippet": "To learn more about our KB-0742 clinical trial please see below or reach out to us at clinicaltrials@kronosbio ... Kronos Bio, Inc. 1300 So. El Camino Real Suite 400 San Mateo, CA 94402 +1 (650) 781-5200. Research Facility . Kronos Bio, Inc. 301 Binney Street 2nd Floor East Cambridge, MA 02142. PARTNERING INQUIRIES. bd@kronosbio.com. MEDIA ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:05:59.769903+00:00",
              "published_date": null,
              "source_hash": "9ce740e48df522b4b498f33fcdf06cef"
            },
            {
              "url": "",
              "title": "Kronos Bio, Inc. - AnnualReports.com",
              "snippet": "Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor KB-0742 as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors and lanraplenib, a next-generation SYK inhibitor, for patients with FLT3-mutated acute myeloid leukemia \u2026",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691607+00:00",
              "published_date": null,
              "source_hash": "a4a2bab0a840ef91ce4e193c5fbbf0db"
            },
            {
              "url": "",
              "title": "Kronos Bio (NASDAQ:KRON) Trading Down 1.8% - What's Next?",
              "snippet": "Shares of Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) traded down 1.8% during trading on Tuesday . The stock traded as low as $0.90 and last traded at $0.95. 337,890 shares were traded during trading,",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:06.249671+00:00",
              "published_date": "2025-01-01T05:40:00+00:00",
              "source_hash": "c06d98313065c264619df21379ffc461"
            },
            {
              "url": "",
              "title": "Kronos sheds staff despite positive data for cancer drug",
              "snippet": "A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a different tack. The Californian biotech is axing 19% of its ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:06:02.078478+00:00",
              "published_date": "2023-11-03T00:00:00+00:00",
              "source_hash": "a8b4c8aa48db266a86db9bf12d5f9596"
            },
            {
              "url": "",
              "title": "Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives",
              "snippet": "Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company ... who dedicated their time and energy to make this clinical trial possible and your commitment to evaluating novel ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:06:02.078488+00:00",
              "published_date": "2024-11-13T21:05:00+00:00",
              "source_hash": "24ba76e3192aef4bc85b59b19a1eab10"
            },
            {
              "url": "",
              "title": "Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma",
              "snippet": "Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company ... is currently enrolling ovarian cancer patients in a Phase 1/2 clinical trial. Preclinical candidate KB-9558 is ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:06:02.078497+00:00",
              "published_date": "2024-11-05T09:00:00+00:00",
              "source_hash": "9157b5aa5e006159f16da5d8f2eec49c"
            },
            {
              "url": "",
              "title": "Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul",
              "snippet": "Kronos Bio, Inc. (NASDAQ:KRON) shares are trading higher ... Benzinga Pro - Click here to start Your 14-Day Trial Now!",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc clinical trial failures",
              "retrieved_at": "2025-01-06T21:06:02.078506+00:00",
              "published_date": "2024-11-27T11:00:00+00:00",
              "source_hash": "66f1592f03f0a46e9f03c6bc6f75adc2"
            },
            {
              "url": "",
              "title": "Struggling Bay Area biotech firm Kronos, once worth $1B, lays off ...",
              "snippet": "Kronos Bio, a struggling Bay Area biotech firm once valued at over $1 billion, is laying off 83% of its staff after other cuts and a failed trial. ... Kronos described the issues as ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502489+00:00",
              "published_date": null,
              "source_hash": "2b06661749b677024e992326a11f5ec9"
            },
            {
              "url": "",
              "title": "Kronos Bio, Inc. SEC 10-Q Report \u2014 TradingView News",
              "snippet": "Kronos Bio, Inc., a biopharmaceutical company focused on developing novel cancer and autoimmune disease therapeutics, has released its Form 10-Q report for the quarter ended September 30, 2024. The report highlights significant financial improvements, strategic initiatives, and the challenges the company faces as it navigates its business ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691527+00:00",
              "published_date": null,
              "source_hash": "005cad4c5c5d5f288ff457d5f8dc7aba"
            },
            {
              "url": "",
              "title": "Kronos Bio announces layoffs, CEO transition | LabPulse.com",
              "snippet": "Kronos Bio announced that it will lay off approximately 83% of its workforce as part of a previously announced cost-reduction strategy. The San Mateo, CA-based Kronos is a biopharmaceutical firm that focuses on developing small-molecule therapeutics for diseases driven by deregulated transcription, including cancers and autoimmune disorders.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691542+00:00",
              "published_date": null,
              "source_hash": "0d0b5e678bed0b5a66dd4da1c99490a2"
            },
            {
              "url": "",
              "title": "Kronos Bio Unveils Promising Autoimmune Candidate Amid Financial Struggles",
              "snippet": "Kronos Bio Inc. has announced a significant milestone in its development pipeline, unveiling KB-7898 as its inaugural candidate for autoimmune diseases, specifically targeting Sj\u00f6gren?s disease. This candidate is a p300 KAT inhibitor, emerging from the company*s proprietary discovery engine that effectively decodes intricate transcription factor regulatory networks. The selection marks a ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691553+00:00",
              "published_date": null,
              "source_hash": "3c67c2095077a836651609ae31d0817c"
            },
            {
              "url": "",
              "title": "Corporate Presentation December 2021 - ir.kronosbio.com",
              "snippet": "Company'sstrategy, intellectual property matters, the Company'sclinical development plans and timelines, regulatory matters, market size ... > 50 known oncogenic role CHALLENGES Context-dependent activity Context-dependent structure ... Kronos Bio portfolio includes two potent, selective clinical-stage SYK inhibitors \u20229.5 nM IC",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691563+00:00",
              "published_date": null,
              "source_hash": "6a39d52459ad5afaff8fa810788c5a89"
            },
            {
              "url": "",
              "title": "Kronos Bio: Underestimated Drug Discovery Platform - Seeking Alpha",
              "snippet": "Kronos Bio, Inc.'s drug discovery platform shows potential in targeting transcription regulatory networks. KRON has catalysts as soon as June, click for more.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691582+00:00",
              "published_date": null,
              "source_hash": "1e1ddc38f4ccb3798fb95a7af57e014a"
            },
            {
              "url": "",
              "title": "Kronos Bio Reports Third Quarter 2024 Financial Results and ... - BioSpace",
              "snippet": "About Kronos Bio, Inc. Kronos Bio is a biopharmaceutical company developing small molecule therapeutics that address deregulated transcription, a hallmark of cancer and autoimmune diseases. Our proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691590+00:00",
              "published_date": null,
              "source_hash": "e36e28f4652692dbef29e082d6867b59"
            },
            {
              "url": "",
              "title": "Kronos Bio Reports Third Quarter 2024 Financial Results and ... - Nasdaq",
              "snippet": "--Kronos Bio, Inc., a company developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription, today reported financial results for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:03.691598+00:00",
              "published_date": null,
              "source_hash": "08c80e9443ce08871d27ea194453219f"
            },
            {
              "url": "",
              "title": "Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives",
              "snippet": "Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing ... engine decodes complex transcription factor regulatory networks to identify druggable cofactors.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:06.249591+00:00",
              "published_date": "2024-11-13T21:05:00+00:00",
              "source_hash": "97dc22733c90c933feb5e8534e0ca4df"
            },
            {
              "url": "",
              "title": "Kronos Bio Announces CEO Transition and Reduction in Force",
              "snippet": "and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:06.249687+00:00",
              "published_date": "2024-11-27T12:30:00+00:00",
              "source_hash": "ced1f98510e760b576431418a12d91fe"
            },
            {
              "url": "",
              "title": "Kronos Bio Inc (KRON) Posted -867.66% Profit Margin Last Year\u2014Can It Hold Up?",
              "snippet": "On Thursday, Kronos Bio Inc (KRON) stock saw a decline, ending the day at $0.92 which represents a decrease of $-0.03 or -3.16% from the prior close of $0.95. The stock opened at $0.95 and touched a low of $0.9 during the day, reaching a high of $0.95. The volume of shares traded was 1.51 million exceeding the average volume of 0.20 million.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:06.249697+00:00",
              "published_date": "2024-12-27T22:35:00+00:00",
              "source_hash": "a47d168809d791844f251702f1cd43a6"
            },
            {
              "url": "",
              "title": "Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul",
              "snippet": "Kronos Bio, Inc. (NASDAQ:KRON) shares are trading higher on Wednesday in the premarket session. The firm announced significant leadership and operational changes. Deborah Knobelman has been ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Kronos Bio Inc Kronos Bio Inc regulatory challenges",
              "retrieved_at": "2025-01-06T21:06:06.249714+00:00",
              "published_date": "2024-11-27T00:00:00+00:00",
              "source_hash": "7bbf3e939f62f356efe2f254affe3999"
            },
            {
              "url": "",
              "title": "Kronos Bio's KB-0742 Shows Promising Safety Profile in ... - CSIMarket",
              "snippet": "Kronos Bio Advances Promising Cancer Therapeutic KB-0742 with Positive Clinical Trial UpdateSan Mateo, Calif. and Cambridge, Mass., March 05, 2024 - Kronos Bio, Inc. (Nasdaq: KRON), a leader in developing innovative cancer therapeutics, recently announced significant progress in their clinical trial for KB-0742, a potential game-changer in cancer treatment. The company has reported positive ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502526+00:00",
              "published_date": null,
              "source_hash": "8f1689f4fb0893ce836247012f80b9a9"
            },
            {
              "url": "",
              "title": "Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives ...",
              "snippet": "Kronos Bio (NASDAQ: KRON) announced the discontinuation of istisociclib development due to unfavorable benefit-risk profile in platinum-resistant ovarian cancer patients. The Board approved exploring strategic alternatives to maximize stockholder value. The company reported $124.9 million in cash and investments as of September 30, 2024, with a Q3 net loss of $14.1 million.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502536+00:00",
              "published_date": null,
              "source_hash": "208890814b9f370a2ddff148486eed1f"
            },
            {
              "url": "",
              "title": "Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at ...",
              "snippet": "Kronos Bio, Inc. \u2014 KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed \u2014 \u2014 KB-0742 continues to show dose linear ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502546+00:00",
              "published_date": null,
              "source_hash": "9f93a02d4f3746044adc47705c406529"
            },
            {
              "url": "",
              "title": "EAP - Kronos Bio",
              "snippet": "This is both to prioritize patient safety and to preserve the integrity of data to provide for scientific assessment of the risks versus the benefits by competent authorities. ... Kronos Bio, Inc. 1300 So. El Camino Real Suite 400 San Mateo, CA 94402 +1 (650) 781-5200. Research Facility . Kronos Bio, Inc. 301 Binney Street 2nd Floor East",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502556+00:00",
              "published_date": null,
              "source_hash": "ba2a2621c615e01336bc3846d99e77bc"
            },
            {
              "url": "",
              "title": "Kronos Bio to Present Clinical Update on Phase 1/2 Trial of - GlobeNewswire",
              "snippet": "SAN MATEO, Calif. and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502565+00:00",
              "published_date": null,
              "source_hash": "19373344c65b5c8411751928b14d2c34"
            },
            {
              "url": "",
              "title": "Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full ...",
              "snippet": "Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results March 15, 2023 First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023 ... after reaching the target engagement goal with an acceptable safety profile. The analysis further showed ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:09.502574+00:00",
              "published_date": null,
              "source_hash": "ab3eb5dea00c879e07e4d0ef9cb9fbb1"
            },
            {
              "url": "",
              "title": "Kronos sheds staff despite positive data for cancer drug",
              "snippet": "A positive clinical trial is usually a signal for a biotech startup to press the accelerator on its spending, but Kronos Bio is taking a ... just generated positive safety and efficacy data ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:17.810803+00:00",
              "published_date": "2023-11-03T00:00:00+00:00",
              "source_hash": "39be36ed57b57bfeff433dcd7aa98617"
            },
            {
              "url": "",
              "title": "Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives",
              "snippet": "Nov. 13, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing ... of istisociclib resulted from a recent safety assessment from the ongoing Phase 1/2 clinical trial ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:17.810863+00:00",
              "published_date": "2024-11-13T21:05:00+00:00",
              "source_hash": "4a06351556edae8c0b07ee75baa11b0f"
            },
            {
              "url": "",
              "title": "Kronos Bio Restructures Workforce and Leadership",
              "snippet": "The latest update is out from Kronos Bio ( (KRON)). Kronos Bio, Inc. is undergoing a significant transformation with an 83% workforce reduction aimed at strategic cost containment by December 31 ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Kronos Bio Inc Kronos Bio Inc patient safety concerns",
              "retrieved_at": "2025-01-06T21:06:17.810876+00:00",
              "published_date": "2024-11-27T11:30:00+00:00",
              "source_hash": "d1b36fb732018146241f877673a6fe5b"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Kronos Bio Inc clinical trial failures",
              "rationale": "Investigate potential risks associated with the failure of clinical trials for KB-0742 or other pipeline candidates",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Kronos Bio Inc regulatory challenges",
              "rationale": "Examine any regulatory hurdles or delays faced by Kronos Bio in gaining approval for its investigational drugs",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Kronos Bio Inc patient safety concerns",
              "rationale": "Look for any reports or controversies related to patient safety in Kronos Bio's clinical trials",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:06:32.501647",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}